Enhanced biliary excretion of lithocholate-3-sulfate by ursodeoxycholate-3,7-disulfate infusion in Eisai hyperbilirubinemic rat (EHBR).
Biliary excretion of lithocholate-3-sulfate and ursodeoxycholate 3,7-disulfate is markedly impaired in EHBR. In the present study, the effects of ursodeoxycholate 3,7-disulfate infusion on lithocholate-3-sulfate excretion were studied in EHBR and Sprague-Dawley rats. Although in control rats, ursodeoxycholate 3,7-disulfate infusion had no effect on biliary lithocholate-3-sulfate excretion, in EHBR it enhanced biliary lithocholate-3-sulfate excretion. Although ursodeoxycholate 3,7-disulfate dose-dependently inhibited lithocholate-3-sulfate binding by rat serum albumin and rat liver cytosol, it did not affect the serum clearance of lithocholate-3-sulfate in EHBR in vivo. These findings indicate that in EHBR, in which the major ATP-dependent organic anion transporter is impaired, the excretory pathway for ursodeoxycholate 3,7-disulfate may interact to that for lithocholate-3-sulfate.
Takikawa
H
H
Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan.
Sano
N
N
Ogasawara
T
T
Yamanaka
M
M
D000818:Animals; D001646:Bile / Q000737:chemistry*; D006932:Hyperbilirubinemia / Q000378:metabolism*; D007262:Infusions, Intravenous; D008095:Lithocholic Acid / Q000031:analogs & derivatives* / Q000032:analysis; D008297:Male; D051381:Rats; D011922:Rats, Mutant Strains; D017207:Rats, Sprague-Dawley; D014580:Ursodeoxycholic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000378:metabolism
C014202:sulfolithocholic acid; D008095:Lithocholic Acid; D014580:Ursodeoxycholic Acid; C101925:ursodeoxycholate-3-sulfate